Join Growin Stock Community!

普生4117.TW Overview

TW StockBiotech. & Medical
(No presentation for 4117)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

普生（4117）Overall Performance

普生（4117）AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

普生（4117） PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

普生（4117）Key Information

普生（4117）Profile

General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development manufacturing organization solutions; blood screening services for hepatitis and HIV; and biomaterial, such as antibody biomaterials and human plasma. In addition, it offers a range of oral care products under the oh care brand. Further, the company serves its diagnostic solutions through clinics and laboratories. General Biologicals Corporation was founded in 1973 and is headquartered in Hsinchu City, Taiwan.

普生（4117）FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.25
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.51
PB Ratio
4.97
Price-to-FCF
5.77
METRIC
VALUE
vs. INDUSTRY
Gross Margin
13.83%
Net Margin
-85.71%
Revenue Growth (YoY)
-44.02%
Profit Growth (YoY)
-84.27%
3-Year Revenue Growth
-2.85%
3-Year Profit Growth
-35.19%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-6.25
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
1.51
PB Ratio
4.97
Price-to-FCF
5.77
Gross Margin
13.83%
Net Margin
-85.71%
Revenue Growth (YoY)
-44.02%
Profit Growth (YoY)
-84.27%
3-Year Revenue Growth
-2.85%
3-Year Profit Growth
-35.19%
default symbol

4117

普生

11.00D

-0.45%

(-0.00)

  • When is 4117's latest earnings report released?

    The most recent financial report for 普生 (4117) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 4117's short-term business performance and financial health. For the latest updates on 4117's earnings releases, visit this page regularly.

  • How much cash does 4117 have?

    At the end of the period, 普生 (4117) held Total Cash and Cash Equivalents of 195.76M, accounting for 0.06 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does 4117 go with three margins increasing?

    In the latest report, 普生 (4117) did not achieve the “three margins increasing” benchmark, with a gross margin of 13.27%%, operating margin of -98.43%%, and net margin of -116.77%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 4117's profit trajectory and future growth potential.